RNA-seq analysis reveals transcriptome changes in livers from Efcab4b knockout mice

RNA-seq analysis reveals transcriptome changes in livers from Efcab4b knockout mice

EFCAB4B is an evolutionarily conserved protein that encodes for the Rab GTPase Rab46, and the CRAC channel modulator, CRACR2A. Previous genome wide association studies have demonstrated the association of EFCAB4B variants in the progression of non-alcoholic fatty liver disease (NAFLD). In this study...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chew W. Cheng, Lucia Pedicini, Cintli Morales Alcala, Fenia Deligianni, Jessica Smith, Ryan D. Murray, Harriet J. Todd, Niamh Forde, Lynn McKeown
Format:	Article
Language:	English
Published:	Elsevier 2025-03-01
Series:	Biochemistry and Biophysics Reports
Subjects:	Human EFCAB4B (Rab46 / CRACR2A) Mouse Efcab4b Liver Non-alcoholic steatohepatitis (NASH) Hepatocarcinoma (HCC) Non-alcoholic fatty liver disease (NAFLD)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405580825000317
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CPF Induces GC2<i><sub>spd</sub></i> Cell Injury via ROS/AKT/Efcab6 Pathway
by: Xuelian Zhang, et al.
Published: (2025-06-01)

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver diseaseKeypoints
by: Robert F. Schwabe, et al.
Published: (2025-08-01)

EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN NOVOSIBIRSK (SIBERIAN FEDERAL DISTRICT): REGIONAL DATA OF OPEN MULTICENTER PROSPECTIVE STUDY DIREG 2
by: V. V. Tsukanov, et al.
Published: (2016-09-01)

PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY)
by: D. Kh. Kalimullina, et al.
Published: (2017-03-01)

Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease
by: Youwen Tan, et al.
Published: (2024-12-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL
by: D. V. Blinov
Published: (2015-12-01)

Gut microbiome in non-alcoholic fatty liver disease
by: Anastasios Mpountouridis, et al.
Published: (2025-01-01)

Liver Cirrhosis as the Outcome of Non-Alcoholic Fatty Liver Disease Associated with PNPLA3 Gene RS738409 Polymorphism
by: I. G. Nikitin, et al.
Published: (2020-03-01)

Impact of Black Pepper (Piper nigrum) Powder on Lipid Profile Parameters Among Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
by: Beenish, et al.
Published: (2025-01-01)

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results
by: V. T. Ivashkin, et al.
Published: (2015-12-01)

Body Composition and Progression of Biopsy‐Proven Non‐Alcoholic Fatty Liver Disease in Patients With Obesity
by: Qianyi Wan, et al.
Published: (2024-12-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Sulforaphane ameliorates non-alcoholic steatohepatitis by KLF4-mediated macrophage M2 polarization
by: Xianghui Huang, et al.
Published: (2024-09-01)

Exosomal novel-miRNA-126 mediates vascular endothelial dysfunction by targeting AhR-NLRP3 pathway in nonalcoholic steatohepatitis
by: Qiuhe Chen, et al.
Published: (2025-03-01)

THE PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN OUTPATIENTS IN THE FAR EAST FEDERAL DISTRICT
by: V. A. Nevzorova, et al.
Published: (2017-05-01)

Non-alcoholic fatty liver disease and cardiovascular pathology: pathogenetic parallels
by: G. Yu. Knorring, et al.
Published: (2024-08-01)

Aloperin improves liver non-alcoholic steatohepatitis in vitro and in vivo
by: Zhongsheng Guo, et al.
Published: (2020-05-01)

Corrigendum: Editorial: Mechanistic insight and therapeutic potential for the management of non-alcoholic steatohepatitis (NASH)
by: Umashanker Navik, et al.
Published: (2024-12-01)

Lactobacillus rhamnosus GG attenuates MASLD/MASH progression by modulating gut microbiota and metabolic pathways
by: Shi-Long Wang, et al.
Published: (2025-07-01)

Diagnostic accuracy of apoptosis markers in non-alcoholic fatty liver disease in children
by: Yu. M. Stepanov, et al.
Published: (2020-12-01)

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
by: Satoshi Shinozaki, et al.
Published: (2025-02-01)

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study
by: Syed Mushfiq, et al.
Published: (2025-01-01)

Changes in direct markers of liver fibrosis in patients with steatohepatitis non-alcoholic and alcoholic origin on the background of obesity and pathology of the biliary tract
by: A. Yu. Filippova
Published: (2017-04-01)

High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction-associated steatotic liver disease
by: Tung-Hung Su, et al.
Published: (2025-07-01)

Features of nonalcoholic fatty liver disease pharmacotherapy in patients with overweight and obesity
by: K. V. Pivtorak
Published: (2017-08-01)

Genetic aspects of non-alcoholic fatty liver disease development
by: V. A. Akhmedov, et al.
Published: (2021-06-01)

STATINS AND URSODEOXYCHOLIC ACID: COOPERATION OR NEUTRALITY?
by: I. N. Grigorieva, et al.
Published: (2016-01-01)

Evolving ideas on non-alcoholic fatty liver disease: from risk to catastrophe
by: Yu. M. Stepanov, et al.
Published: (2020-04-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

Non-Alcoholic Fatty Liver Disease and the Risk of Liver Fibrosis in Chronic Hepatitis B Patients
by: Andri Sanityoso Sulaiman, et al.
Published: (2023-09-01)

A CLINICAL CASE OF DRUG HEPATITIS A WOMAN WHO IS PREGNANT WITH OBESITY
by: I. O. Makarov, et al.
Published: (2016-05-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

Steatohepatitis in Children with Obesity
by: Alexander A. Zvyagin, et al.
Published: (2021-08-01)

Possible Role of Platelets in the Development and Progression of Non-Alcoholic Fatty Liver Disease
by: Anna F. Sheptulina, et al.
Published: (2025-03-01)

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Pieralice S, et al.
Published: (2025-07-01)

Diagnostic and pathogenetic significance of apolipoprotein disorders in patients with alcoholic fatty liver
by: Mladenović Bojan, et al.
Published: (2017-01-01)

SMYD2 inhibitors have no effect in improving non-alcoholic steatohepatitis in mice
by: Lanzexin Yang, et al.
Published: (2025-06-01)

Changes in indicators of fibrosis in patients with alcoholic liver cirrhosis associated with non-alcoholic fatty liver disease depending on the stage of cirrhosis
by: N. R. Matkovska, et al.
Published: (2020-06-01)